Assess changes in plaque over time
Cleerly COMPARE provides longitudinal disease evaluation so providers can assess changes in CAD progression — key to heart attack prevention
Guide personalized treatment
The report from Cleerly COMPARE helps inform treatment decisions, allowing you to individualize therapy to specific patient needs
Human-refined
The AI-generated report is reviewed, refined, and confirmed by a human reviewer to ensure that you’re working with the precise, consistent analysis data
From plaque analysis to lifestyle optimization
- Evaluation and monitoring of plaque, including low-density-non-calcified plaque, non-calcified plaque, and calcified plaque, can help physicians assess a patient’s risk above and beyond stenosis severity and aggregate plaque burden1
- Clinically relevant insights provide a framework for physicians to initiate, intensify, or de-intensify medical management of patients with CAD2
reduction in the rate of death and non-fatal heart attacks in patients with chest pain that receive a CCTA vs patients that did not at 5 years3
Evaluate plaque volume from scan to scan |
In some cases, plaque may regress between scans, indicating that the patient's therapy is effective |
Analyze in lesion-by-lesion detail |
